Art

J-GLOBAL ID：201902210644412554   Reference number：19A0962919

Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance

変異FLT3急性骨髄性白血病における発癌シグナル伝達の標的化:最小耐性への経路【JST・京大機械翻訳】

Author (15)： Staudt Dilana (School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan, NSW 2308, Australia) ,  Staudt Dilana (Priority Research Centre for Cancer Research, Innovation & Translation, Faculty of Health & Medicine, Hunter Medical Research Institute, New Lambton Heights, NSW 2305, Australia) ,  Murray Heather C. (School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan, NSW 2308, Australia) ,  Murray Heather C. (Priority Research Centre for Cancer Research, Innovation & Translation, Faculty of Health & Medicine, Hunter Medical Research Institute, New Lambton Heights, NSW 2305, Australia) ,  McLachlan Tabitha (School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan, NSW 2308, Australia) ,  McLachlan Tabitha (Priority Research Centre for Cancer Research, Innovation & Translation, Faculty of Health & Medicine, Hunter Medical Research Institute, New Lambton Heights, NSW 2305, Australia) ,  Alvaro Frank (Priority Research Centre for Cancer Research, Innovation & Translation, Faculty of Health & Medicine, Hunter Medical Research Institute, New Lambton Heights, NSW 2305, Australia) ,  Alvaro Frank (John Hunter Children’s Hospital, Faculty of Health and Medicine, University of Newcastle, New Lambton Heights, NSW 2305, Australia) ,  Enjeti Anoop K. (Priority Research Centre for Cancer Research, Innovation & Translation, Faculty of Health & Medicine, Hunter Medical Research Institute, New Lambton Heights, NSW 2305, Australia) ,  Enjeti Anoop K. (Calvary Mater Hospital, Hematology Department, Waratah, NSW 2298, Australia) ,  Enjeti Anoop K. (NSW Health Pathology North, John Hunter Hospital, New Lambton Heights, NSW 2305, Australia) ,  Verrills Nicole M. (School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan, NSW 2308, Australia) ,  Verrills Nicole M. (Priority Research Centre for Cancer Research, Innovation & Translation, Faculty of Health & Medicine, Hunter Medical Research Institute, New Lambton Heights, NSW 2305, Australia) ,  Dun Matthew D. (School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan, NSW 2308, Australia) ,  Dun Matthew D. (Priority Research Centre for Cancer Research, Innovation & Translation, Faculty of Health & Medicine, Hunter Medical Research Institute, New Lambton Heights, NSW 2305, Australia)
Material： International Journal of Molecular Sciences (Web)  (Int J Mol Sci (Web))
Volume： 19  Issue： 10  Page： 3198  Publication year： 2018 
JST Material Number： U7038A  ISSN： 1422-0067  CODEN： IJMCFK  Document type： Article
Article type： 文献レビュー  Country of issue： Switzerland (CHE)  Language： ENGLISH (EN)

Abstract/Point： The identification of recurren...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=19A0962919&from=J-GLOBAL&jstjournalNo=U7038A") }}

Thesaurus term： *carcinogenesis ,  human(primates) ,  *targeting ,  receptor tyrosine kinase ,  gene ,  recurrence ,  Individualized Medicine ,  diagnosis ,  *cellular signal transduction ,  *acute myeloid leukemia ,  molecular target therapy ,  mutation
Semi thesaurus term： チロシンキナーゼ阻害剤 ,  治療標的 ,  予後不良 ,  *fms様チロシンキナーゼ3 , 【Automatic Indexing@JST】

Author keywords (4)： acute myeloid leukemia ,  FLT3 ,  tyrosine kinase inhibitors ,  resistance

JST classification (4)： Basic research of antitumor(=antineoplastic)drugs  (GW16010A) ,  Genetic variation  (EC01030Y) ,  Chemistry,biochemistry and pathology of tumors(=neoplasms)  (GE02030N) ,  Drug therapy(=pharmacotherapy)for tumors  (GE03032C)

Reference (191)：

• Bozic, I.; Antal, T.; Ohtsuki, H.; Carter, H.; Kim, D.; Chen, S.; Karchin, R.; Kinzler, K.W.; Vogelstein, B.; Nowak, M.A. Accumulation of driver and passenger mutations during tumor progression. Proc. Natl. Acad. Sci. USA 2010, 107, 18545-18550.
• Sakamoto, K.M.; Grant, S.; Saleiro, D.; Crispino, J.D.; Hijiya, N.; Giles, F.; Platanias, L.; Eklund, E.A. Targeting novel signaling pathways for resistant acute myeloid leukemia. Mol. Genet. Metab. 2015, 114, 397-402.
• National Cancer Institute, DCCPS, Surveillance Research Program; Surveillance, Epidemiology, and End Results (SEER) Program Research Data (1973-2015). 2015. Available online: https://www.seer.cancer.gov (accessed on 15 May 2018).
• Dohner, H.; Weisdorf, D.J.; Bloomfield, C.D. Acute Myeloid Leukemia. N. Engl. J. Med. 2015, 373, 1136-1152.
• Faulk, K.; Gore, L.; Cooper, T. Overview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemia. Paediatr. Drugs 2014, 16, 213-227.

Terms in the title (8)： 変異 ,  flt3 ,  急性骨髄性白血病 ,  発癌 ,  シグナル伝達 ,  標的化 ,  耐性 ,  経路